Inovio has developed novel, multi-subtype synthetic vaccines for foot-and-mouth disease (FMD), one of the most infectious diseases affecting farm animals including cattle, swine, sheep and goats and a serious threat to global food supply. Because Inovio's SynCon® vaccines cannot cause the targeted disease, they provide a safe approach to potentially protect against FMD. Following administration of these vaccines in swine and sheep, all the vaccines induced strong antibody and T-cell immune responses.

Under a Cooperative Research and Development Agreement, the U.S. Department of Homeland Security (DHS) Science and Technology Directorate Plum Island Animal Disease Center is currently evaluating the efficacy of Inovio's FMD vaccines in cattle, sheep, and pigs.

Inovio owns a majority interest in VGX Animal Health Inc., which is developing pharmaceutical products for animal health applications. This includes a growth hormone-releasing hormone treatment for cancer and anemia in dogs and cats. The company also markets LifeTide™ animal growth hormone for swine. LifeTide™ is one of only four DNA-based treatments approved for use in animals and is the only DNA-based agent delivered using electroporation that has been granted marketing approval (Australia).

Contact Inovio about business opportunities in animal health products.